研究单位：[1]Tongji Hospital,Huazhong University of Science and Technology,Wuhan,Hubei,China,430030
研究目的：
To Hepatocellular carcinoma (HCC), radical resection is still one of the best treatments for HCC, but the recurrence rate is as high as 70% five years after the operation, and the prognosis of patients with high-risk recurrence factors such as portal vein tumor thrombus (PVTT) and microvascular invasion (MVI) is even worse, so it is particularly urgent to find effective postoperative adjuvant treatment. Immune checkpoint inhibitors(such as PD1) may improve the prognosis of these patients.
